Innate Pharma S.A.
Innate Pharma S.A. (IPHYF) Revenue
Annual & quarterly revenue history · segment & region breakdown
IPHYF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsInnate Pharma S.A. trailing twelve-month (TTM) revenue is $0.02B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Innate Pharma S.A. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Innate Pharma S.A. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Innate Pharma S.A.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IPHYF revenue · 4 questionsIPHYF's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Innate Pharma S.A. SEC filings · GAAP · Innate Pharma S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026